Chlorotrianisene

Acetazolamide Bucloxic acid Butalamine HCI Chlorotrianisene Chlorquinaldol Clenbuterol Diazoxide Enflurane Floxacillin Flucloronide Isoflurophate Lindane Methazolamide Metoclopramide HCI Oxacillin sodium Chloroacetaldehyde Benzthiazide... 

Tabalgin - Acetaminophen Tabrien Feprezone Tacaryl Methdilazine HCI TACE Chlorotrianisene Tacef Cefmenoxime TACE FN - Chlorotrianisene Tachiciclina - Methacycline Tachionin Trichlormethiazide Tachipirina Acetaminophen... 

Triacort - Triamcinolone acetonide Triaderm Triamcinolone acetonide Triadol Benorylate Triafed Triprolidine Triagen Chlorotrianisene Triaget - Triamcinolone acetonide Trialona Triamcinolone Trielona Triamcinolone acetonide Triamalone Triamcinolone acetonide Triamcin Triamcinolone diacetete Triamcort Triamcinolone Triemetine Triethylenemelemine Triam Forte Triamcinolone diacetete Trieminic Pyrilamine... 

CifiHjjNO 33216-38-5) see Pentazocine 4-methoxy-a,a-bis(4-methoxyphenyl)benzeneethanol (C22H24O4 1817-87-4) see Chlorotrianisene... 

Estrogens, estrone (28.1.9), estradiol (28.1.17), ethynylestradiol (28.1.26), diethylstilbe-strol (28.1.33), and chlorotrianisene (30.5.2), are used for palliative treatment of postmenopausal breast cancer, prostate cancer, and breast cancer in men. It is highly probable that the mechanism of action is similar to the mechanism of action of androgens. 

In addition to estrogen agonists based on steroid structures, a variety of nonsteroidal estrogens have also been synthesized and used clinically dienestrol (5.30), diethyl-stilbestrol (5.31), benzestrol (5.32), hexestrol (5.33), methestrol (5.34), methallenestril (5.35), and chlorotrianisene (5.36). 

In addition to the steroidal estrogens, a variety of nonsteroidal compounds with estrogenic activity have been synthesized and used clinically. These include dienestrol, diethylstilbestrol, benzestrol, hexestrol, methestrol, methallenestril, and chlorotrianisene (Figure 40-3). 

Clomiphene citrate, a partial estrogen agonist, is closely related to the estrogen chlorotrianisene (Figure 40-3). This compound is well absorbed when taken orally. It has a half-life of 5-7 days and is excreted primarily in the urine. It exhibits significant protein binding and enterohepatic circulation and is distributed to adipose tissues. 

Chlorotrianisene does not bind in vitro to the uterine estrogen receptor but has potent estrogenic and antiestrogenic actions in vivo, suggesting that it is a prodrug. Its antiestrogenic activity has been proposed to be due to a reactive intermediate (1). 

In 50 postpartum women who took chlorotrianisene for lactation suppression in a double-blind, randomized, placebo-controlled study, antithrombin III concentrations were significantly lower on the third day postpartum compared with placebo (2). 

Niebyl JR, Bell WR, Schaaf ME, Blake DA, Dubin NH, King TM. The effect of chlorotrianisene as postpartum lactation suppression on blood coagulation factors. Am J Obstet Gynecol 1979 134(5) 518-22. 

---